TIDMYGEN

RNS Number : 1676H

Yourgene Health PLC

26 July 2023

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

Five-year contract extension with Illumina

Manchester , UK - 26 July 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces that it has signed a five-year contract extension with Illumina Inc. ("Illumina"). The contract is a restated licence and supply agreement for Yourgene's sequencing based NIPT IVD products, which will now run until September 2028.

The restated licence provides seamless continuity for existing customers and allows Yourgene to continue its product development roadmaps for NIPT and other future applications in the field of precision medicine, as the Company looks to further penetrate key international markets such as Americas, UK, Europe and Australia.

Lyn Rees, Chief Executive Officer of Yourgene, commented: "We are delighted to continue our partnership with Illumina following a successful five years of working together to date. This provides us with a good opportunity to further develop exciting market opportunities in NIPT across many key markets ."

The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                           Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                                        investors@yourgenehealth.com 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                          Tel: +44 (0)20 7213 0880 
Liam Murray / Ludovico Lazzaretti 
 
Singer Capital Markets (Corporate Broker)                                     Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George Tzimas 
 
Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
Paul McManus / Alice Woodings / Lianne Applegarth                   Mob: 07980 541 893 / 07407 804 654 
                                                                                       / 07584 391 303

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

Building on our expertise in genomic technology, Yourgene's Ranger(R) Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger(R) Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei (divestment pending), Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUVVNRORUBUAR

(END) Dow Jones Newswires

July 26, 2023 02:00 ET (06:00 GMT)

Yourgene Health (LSE:YGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Yourgene Health.
Yourgene Health (LSE:YGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Yourgene Health.